Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenoxypropanolamines as selective beta 1-receptor agonists.

C Raper, G A McPherson, E Malta

    Circulation Research
    |June 1, 1980
    PubMed
    Summary

    Introducing an oxymethylene link in beta-receptor agonists creates compounds that stimulate beta 1-receptors while weakly blocking beta-receptors. This modification yields novel pharmacological profiles for potential therapeutic applications.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    An unusual cause of persistent vomiting.

    Postgraduate medical journal·2003
    Same author

    A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.

    Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·2001
    Same author

    Colonic carcinoma after ureterosigmoidostomy.

    Postgraduate medical journal·2000
    Same author

    The identification of a potent imidazoline-based vascular K(ATP) channel antagonist.

    Naunyn-Schmiedeberg's archives of pharmacology·2000
    Same author

    Anal sphincter disruption from a snowboarding injury.

    Journal of the Royal Society of Medicine·2000
    Same author

    The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

    Journal of the neurological sciences·1999

    Area of Science:

    • Medicinal Chemistry
    • Pharmacology
    • Drug Discovery

    Background:

    • Beta-receptor agonists are crucial in treating various conditions.
    • Modifying existing drug structures can alter receptor interactions.
    • Understanding structure-activity relationships is key to developing new therapeutics.

    Purpose of the Study:

    • To investigate the pharmacological effects of introducing an oxymethylene link into beta-receptor agonists.
    • To characterize the resulting compounds' activity at beta 1 and beta receptors.
    • To explore potential therapeutic applications of these modified agonists.

    Main Methods:

    • Synthesis of novel compounds featuring an oxymethylene linker.
    • In vitro receptor binding assays to determine affinity and efficacy.

    Related Experiment Videos

  • Functional assays to assess beta 1-receptor stimulation and beta-receptor antagonism.

    • Main Results:

    • Compounds with the oxymethylene link exhibited potent beta 1-receptor stimulant activity.
    • These compounds also displayed weak beta-receptor antagonistic properties.
    • The structural modification successfully modulated receptor subtype selectivity.

    Conclusions:

    • The oxymethylene linker is a valuable modification for designing beta-receptor agonists.
    • These compounds represent a new class of agents with mixed beta 1-agonist/beta-antagonist profiles.
    • Further research may lead to novel treatments leveraging this unique pharmacological action.